In this issue, you'll find exciting news and original stories, a focus on our commitment on Epilepsy and our strategy to becoming a recognized Employer of Choice.
ONTOZRY® (cenobamate) receives European Commission approval for the treatment of drug-resistant focal-onset seizures in adults
Angelini Pharma announced today that the EC has granted marketing authorization for ONTOZRY®.
Four thousand European citizens were interviewed by SWG on behalf of Angelini Pharma on the occasion of the Purple Day, the international day of awareness about epilepsy. According to the majority of respondents, people with epilepsy are perfectly normal people, but 40% would not talk about the disease at work.